Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun 13;7(11):2586-2589.
doi: 10.1182/bloodadvances.2022009622.

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV

Paolo Strati  1 , Oren Pasvolsky  2   3 , Lei Feng  4 , Guofan Xu  5 , Sanjit O Tewari  5 , Jaimole Varghese  1 , Karla Ow  1 , Minifrida Santiago  1 , Ajlan Al Zaki  1 , Andrew Jallouk  1 , Sattva S Neelapu  1 , Partow Kebriaei  2 , Elizabeth J Shpall  2 , Sairah Ahmed  1   2
Affiliations
Comment

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV

Paolo Strati et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.S. is a consultant for Roche-Genentech, Kite-Gilead, Hutchison MediPharma, AstraZeneca-Acerta, ADC Therapeutics, Sobi, and TG Therapeutics, and has received research funds from Sobi, AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics. S.A. has research support to institution for clinical trials from Seattle Genetics, Merck, Xencor, Chimagen, and Tessa Therapeutics; has membership on Tessa Therapeutic’s and Chimagen’s scientific advisory committee; serves on the data safety monitoring board for Myeloid Therapeutics; and is a consultant for ADC Therapeutics and Kite-Gilead. S.O.T. holds private stocks in Starton Therapeutics, CoapTech LLC, Lutroo Imaging, NeuroMedica, Beyond Physician, and Xense Inc. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Cumulative incidence of relapse/progression according to TMTV. (A) Distribution of the TMTV in patients who underwent ASCT or CART. (B) Example of low and high TMTV PR. (C) Cumulative incidence of relapse/progression in patients with a low TMTV PR. (D) Cumulative incidence of relapse/progression in patients with a high TMTV PR.
See this image and copyright information in PMC

Comment on

References

    1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540–1545. - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. - PMC - PubMed
    1. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. - PubMed
    1. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. - PubMed

MeSH terms